NEW YORK (GenomeWeb News) — Canadian biomarker company Miraculins has withdrawn its offer to acquire diagnostics developer IBEX technologies.
In mid-November Winnipeg-based Miraculins made an unsolicited offer to acquire IBEX through a stock deal that would exchange one common Miraculins share for five shares in IBEX.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.